Novel therapies for chronic myelogenous leukemia

被引：34

作者：

Jahagirdar, BN ^{[1
]}

Miller, JS ^{[1
]}

Shet, A ^{[1
]}

Verfaillie, CM ^{[1
]}

机构：

[1] Univ Minnesota, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA

来源：

EXPERIMENTAL HEMATOLOGY | 2001年 / 29卷 / 05期

关键词：

D O I：

10.1016/S0301-472X(01)00633-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation, We have systematically review-ed each of these novel therapeutic approaches in this article. (C) 2001 International Society for Experimental Hematology, Published by Elsevier Science Inc.

引用

页码：543 / 556

页数：14

共 213 条

[81] A novel BCR-ABL, fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia [J].

Hochhaus, A ;

Reiter, A ;

Skladny, H ;

Melo, JV ;

Sick, C ;

Berger, U ;

Guo, JQ ;

Arlinghaus, RB ;

Hehlmann, R ;

Goldman, JM ;

Cross, NCP .

BLOOD, 1996, 88 (06) :2236-2240

[82] Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells:: a transgenic study for blast crisis of human CML [J].

Honda, H ;

Ushijima, T ;

Wakazono, K ;

Oda, H ;

Tanaka, Y ;

Aizawa, S ;

Ishikawa, T ;

Yazaki, Y ;

Hirai, H .

BLOOD, 2000, 95 (04) :1144-1150

[83] INHIBITION OF ABL ONCOGENE TYROSINE KINASE INDUCES ERYTHROID-DIFFERENTIATION OF HUMAN MYELOGENOUS LEUKEMIA K562 CELLS [J].

HONMA, Y ;

OKABEKADO, J ;

KASUKABE, T ;

HOZUMI, M ;

UMEZAWA, K .

JAPANESE JOURNAL OF CANCER RESEARCH, 1990, 81 (11) :1132-1136

[84]

HONMA Y, 1989, CANCER RES, V49, P331

[85] The therapeutic potential of ribozymes [J].

James, HA ;

Gibson, I .

BLOOD, 1998, 91 (02) :371-382

[86] Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation:: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity [J].

Jiang, YH ;

Zhao, RCH ;

Verfaillie, CM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10538-10543

[87]

JIANG YZ, 1995, EXP HEMATOL, V23, P1167

[88]

JIANG YZ, 1993, BONE MARROW TRANSPL, V11, P133

[89]

JIANG YZ, 1991, BONE MARROW TRANSPL, V8, P253

[90]

Kantarjian H, 2000, BLOOD, V96, p470A

← 4 5 6 7 8 9 10 11 12 13 →